Objective: Detection the presumptive prevalence of silent celiac disease in patients with type 1 diabetes mellitus with determination of which gender more likely to be affected.
Methods: One hundred twenty asymptomatic patients [75 male , 45 female] with type 1 diabetes mellitus with mean age ± SD of 11.25 ± 2.85 year where included in the study . All subjects were serologically screened for the presence of anti-tissue transglutaminase IgA antibodies (anti-tTG antibodies) by Enzyme-Linked Immunosorbent Assay (ELISA) & total IgA was also measured for all using radial immunodiffusion plate . Anti-tissue transglutaminase IgG was selectively done for patients who were expressing negative anti-tissue transglutaminase IgA with low total IgA levels & results were compared to that obtained from healthy 60 persons with mean age ± SD for them was 15.25 ± 3.85 year . Al - Kindy Col Med J 2012 ; Vol .8 No. (2) p: 132
Results : Fourteen out of one hundred twenty (11.66 % ) diabetic patients had expressed positivity to anti-tissue transglutaminase IgA compared to 1/60 ( 1.66 %) of non diabetic patients who had expressed such positivity , P value equals to 0.0221 & it is considered to be statistically significant. Three out of one hundred twenty (2.5 % ) diabetic patients had expressed total IgA deficiency whereas all of non diabetic patients were expressing total IgA within the normal range , P value equals to 0.55 & it is considered to be not statistically significant. All of three diabetic patients with total IgA deficiency were not showing positivity to anti-tissue transglutaminase IgG . Six mals & Eight female of those with type 1 diabetes mellitus had expressed positivity to anti-tissue transglutaminase IgA , P value equals to 0.1426 & it is considered to be not statistically significant .
Conclusion : There is an increased prevalence of IgA antitissue transglutaminase antibodies ( 11.66 % ) in children & adolescent with type 1 diabetes mellitus in comparison with control group.
The pandemic of coronavirus disease 2019 (COVID-19), first reported in China, in December 2019 and since then the digestive tract involvement of COVID-19 has been progressively described. In this review, I summed recent studies, which have addressed the pathophysiology of COVID-19-induced gastrointestinal symptoms, their prevalence, and bowel pathological and radiological findings of infected patients. The effects of gut microbiota on SARS-CoV-2 and the challenges of nutritional therapy of the infected patients are depicted. Moreover, I provide a concise summary of the recommendations on the management of inflammatory bowel disease, colorectal cancer, and performing endoscopy in the COVID era. Finally, the COVID pancreatic re
... Show More